First EFIC® Symposium Societal Impact of Pain - SIP

Ad Rietveld MD MBA
RJW & Partners Ltd.
Ad Rietveld
Ad Rietveld has spent most of his professional
career in the pricing and reimbursement of
pharmaceuticals. He is one of the few medical
doctors whose experience in the pharmaceutical
market encompasses clinical work, pharmaceutical
industry and government. With a
degree in medicine, he worked in medical practice
as a general practitioner in the Netherlands
and as a hospital house officer.
He gained his MBA at the Rotterdam School
of Management and then worked in marketing
for Solvay Duphar. Ad then worked for 11 years
in the Dutch Ministry of Health. In his last position,
he was deputy director of the Department
for Pharmaceutical Affairs, covering cost control
of medicines and medical devices and managing
complex regulatory issues. He and his
40 professional staff were responsible for the
development and implementation of pharmaceutical
cost containment policies, including
the development of a reference price system
and price controls.
Through his experience, Ad has gained a thorough
understanding of pharmaceutical policy
issues in the field of drug price reimbursement.
He has a detailed knowledge of social health
care insurance systems, and has acted as a
member of international advisory and governmental
bodies, including the European Commission's
Pharmaceutical Pricing Transparency
Committee. He has been closely involved with
the WHO and World Bank in the development
of international pharmaceutical policies with
emphasis on emerging EU countries. Among
others, he has helped developing the P&R systems
in Vietnam, Serbia, Romania and Albania.
In August 2000, Ad Rietveld joined Cambridge
Pharma Consultancy (now part of IMS Health
Consulting). Over the years, he has worked on
a wide range of pricing and market access assignments
in numerous therapeutic areas.
81